Drug Trial Radar · NCT01861912
Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Jun 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
258
Planned (sponsor's estimate)
Start
Jun 2013
Primary completion
Jun 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Guangdong Provincial People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.
Conditions
- Carcinoma, Hepatocellular
Interventions
Arsenic trioxide TACEDevice
Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities
Arsenic trioxide intravenous infusionDrug
Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE.
lipiodolDrug
Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
NaCl solutionDrug
250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to ProgressionTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.